ProCE Banner Series

Individualized Multidisciplinary CLL Care: Practical Application of Guidelines and Emerging Data

Interact with an expert during a 1-hour CME/CNE/CPE-certified live meeting examining recent advances and current NCCN-recommended best practices in the treatment of CLL. Register today!

To Register: Please click the green “Learn More” button below. On the next page, select “Register for Virtual Event.” Once registered, you will receive a confirmation email. Follow-up emails with event details will be sent as the event nears.

  AAPA
  | ACPE
  | AMA
  | ANCC
Who Should Attend

This educational program is intended for hematologists, medical oncologists, pathologists, PAs, nurses, pharmacists, and other HCPs who treat patients with CLL.

All Events

Past Events

November

28

2023

Individualized Multidisciplinary CLL Care: Practical Application of Guidelines and Emerging Data

4:30 PM - 5:30 PM Eastern Time (ET)

Virtual

Private Event | Host Group SC, Georgetown, South Carolina

December

19

2023

Individualized Multidisciplinary CLL Care: Practical Application of Guidelines and Emerging Data

7:00 PM - 8:00 PM Eastern Time (ET)

In-person

Private Event, Garden City, New York

January

09

2024

Individualized Multidisciplinary CLL Care: Practical Application of Guidelines and Emerging Data [Open Registration]

7:30 AM - 8:30 AM Pacific Time (PT)

Virtual

CCO Simulcast | Host Group ID, Post Falls, Idaho

March

16

2024

Individualized Multidisciplinary CLL Care: Practical Application of Guidelines and Emerging Data

11:30 AM - 12:30 PM Pacific Time (PT)

In-person

Private Event | Host Group in WA, Spokane, Washington

March

25

2024

Individualized Multidisciplinary CLL Care: Practical Application of Guidelines and Emerging Data [Open Registration]

11:30 AM - 12:30 PM Eastern Time (ET)

Virtual

CCO Simulcast | Host Group MD, Baltimore, Maryland

Faculty

ProCE Banner Faculty
Shuo Ma, MD, PhD

Professor of Medicine
Division of Hematology/Oncology
Robert H. Lurie Comprehensive Cancer Center
Northwestern University Feinberg School of Medicine
Chicago, Illinois

ProCE Banner Faculty
Sameer A. Parikh, MBBS

Consultant, Division of Hematology
Chair, CLL Disease Team
Vice Chair, Lymphoid Malignancies Disease Group
Mayo Clinic Comprehensive Cancer Center
Associate Professor of Medicine
Assistant Professor of Oncology
Mayo Clinic
Rochester, Minnesota

ProCE Banner Faculty
Meghan C. Thompson, MD

Assistant Attending, Leukemia Service
Memorial Sloan Kettering Cancer Center
New York, New York

ProCE Banner Faculty
Chaitra S. Ujjani, MD

Clinical Director of Lymphoma
Fred Hutchinson Cancer Center
Clinical Professor of Medicine
University of Washington
Seattle, Washington

Topics

  • Modern treatment algorithm for optimizing treatment for CLL/SLL
    • NCCN guideline recommendations
    • Key considerations for the selection of first-line therapy
    • Duration of treatment (fixed-duration vs continuous treatment)
    • Considerations for the selection of second-line and subsequent therapy
    • Strategies for the management of adverse events
  • On the horizon
    • MRD-guided treatment
    • Emerging roles of noncovalent BTK inhibitors
    • CAR T-cell therapy
  • Audience question and answer session

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.

CME/CE Info

Goal Statement
The goal of this program is to improve the knowledge, competence, and performance of learners in effort to optimize treatment for patients with chronic lymphocytic leukemia (CLL).

Target Audience
This educational program is intended for hematologists, medical oncologists, pathologists, PAs, nurses, pharmacists, and other HCPs who treat patients with CLL. 

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Apply evidence-based guideline recommendations to optimize clinical outcomes in patients with CLL/SLL taking into consideration prognostic variables, response to prior therapy, comorbidities, and patient preference
  • Appraise intraclass differences in selectivity, binding, efficacy, and adverse event profiles of agents with the similar molecular target used to treat CLL/SLL 
  • Plan an individual treatment approach, including sequence of therapy for relapsed/refractory CLL/SLL, based on the available evidence and recommendations outlined in the NCCN Guidelines

Accreditation

Joint Accreditation Statement

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

NCCN designates this live activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

NCCN designates this educational activity for a maximum of 1.0 contact hour.

Continuing Pharmacy Education

NCCN designates this application-based continuing education activity for 1.o contact hour (0.10 CEUs) of continuing education credit. Universal Activity Number: JA4008196-0000-23-104-L01-P 

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Associate/Physician Assistant Continuing Medical Education

NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.

NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers, and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose all financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates, and discloses to learners all relevant financial relationships. In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. Full disclosure of faculty relationships will be made prior to the activity.

Acknowledgement

Provided by the National Comprehensive Cancer Network (NCCN) in collaboration with Clinical Care Options, LLC.

Supported by an educational grant from AstraZeneca.